EndLyz Therapeutics

Executive Summary

EndLyz Therapeutics is a UK-based biotechnology company founded in 2021, dedicated to developing disease-modifying small-molecule therapies for neurodegenerative diseases, with an initial focus on Parkinson's disease and related dementias. The company's core hypothesis centers on lysosomal dysfunction as a key driver of neurodegeneration. Specifically, EndLyz targets two lysosomal transporters, ATP13A2 and ATP10B, aiming to restore endo-lysosomal function and thereby halt disease progression. Founded on cutting-edge research from University College London, the company has built a proprietary platform to identify small molecules that modulate these transporters. While still in preclinical stages, EndLyz has demonstrated proof-of-concept in cellular and animal models of Parkinson's disease, showing rescue of lysosomal deficits and neuroprotection. The company is now advancing its lead candidates toward IND-enabling studies. EndLyz's approach is differentiated by its focus on restoring lysosomal health rather than merely managing symptoms, offering potential for disease modification. As a private company with a strong scientific foundation, EndLyz is positioned to attract further investment and partnerships. Success in preclinical development could lead to first-in-human trials within the next two to three years, addressing a significant unmet need in neurodegenerative disease therapeutics.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round70% success
• Q4 2026Presentation of Preclinical Data at Major Neurology Conference80% success
• Q1 2027Initiation of IND-Enabling Studies for Lead Candidate60% success